If you or a loved one is taking Tysabri, you may be concerned about the risk of progressive multifocal leukoencephalopathy (PML), a rare brain infection. The scientific understanding of this association has evolved through years of pharmacovigilance and post-marketing studies. This page provides an update on the latest research, including symptom recognition, risk factors, and FDA guidance.
Tysabri (natalizumab) is a monoclonal antibody used to treat multiple sclerosis and Crohn's disease. Its prescribing information includes a boxed warning stating that Tysabri increases the risk of progressive multifocal leukoencephalopathy (PML), an opportunistic viral infection of the brain caused by the JC virus (JCV) that usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). PML typically occurs only in patients who are immunocompromised, and Tysabri treatment creates a state of immune suppression that allows JCV to reactivate and infect the brain (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Three risk factors for PML in Tysabri-treated patients have been identified: the presence of anti-JCV antibodies, longer treatment duration (especially beyond 2 years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Patients who are anti-JCV antibody positive have a higher risk for developing PML (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These factors should be considered in the context of expected benefit when initiating and continuing treatment with Tysabri (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The clinical presentation of PML includes progressive neurological deficits such as cognitive impairment, motor weakness, and visual disturbances. Diagnosis is confirmed by brain MRI showing characteristic white matter lesions and detection of JCV DNA in cerebrospinal fluid. Healthcare professionals should monitor patients on Tysabri for any new sign or symptom that may be suggestive of PML (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Tysabri dosing should be withheld immediately at the first sign or symptom suggestive of PML (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Because of the risk of PML, Tysabri is available only through a restricted distribution program called the TOUCH Prescribing Program (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).
The mechanistic pathway linking Tysabri to PML involves its action as an alpha-4 integrin antagonist. Tysabri binds to alpha-4 integrin on the surface of immune cells, preventing their adhesion to endothelial cells and subsequent migration across the blood-brain barrier. This reduces immune surveillance in the central nervous system, allowing JCV to reactivate and infect oligodendrocytes, leading to demyelination and the characteristic lesions of PML. In clinical trials, PML occurred in three patients who received Tysabri (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Two cases were observed in the 1869 patients with multiple sclerosis who were treated for a median of 120 weeks; these two patients had received Tysabri in addition to interferon beta-1a (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The third case occurred after eight doses in one of the 1043 patients with Crohn's disease who were evaluated for PML (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These cases demonstrate that PML can occur within the first year of treatment, though risk increases with longer exposure. Causation-related considerations for affected patients involve establishing that PML developed during or after Tysabri treatment, with no other clear cause of immunosuppression. The timeline between exposure and documented harm can vary. In clinical trials, PML occurred after 8 doses (approximately 2 months) in one patient and after a median of 120 weeks (approximately 2.3 years) in two patients (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Post-marketing data from the FDA Adverse Event Reporting System (FAERS) show that Tysabri is associated with a wide range of adverse events, with fatigue (19,150 reports), multiple sclerosis relapse (16,691 reports), and headache (9,626 reports) being the most frequently reported (https://api.fda.gov/drug/event.json?search=patient.drug.medicinalproduct:TYSABRI). While PML is not among the most frequently reported events in FAERS, its severity and the clear causal link established in clinical trials and labeling make it a critical safety concern.
The adequacy of warnings regarding Tysabri and PML is addressed through the boxed warning, which is the strongest warning required by the FDA. The warning clearly states that Tysabri increases the risk of PML and that it usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). It also identifies the three known risk factors and instructs healthcare professionals to monitor patients and withhold dosing at the first sign of PML (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The TOUCH Prescribing Program further restricts distribution to ensure that only prescribers and patients who are aware of the risks can access the drug (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). In summary, Tysabri carries a well-documented risk of PML, with a clear mechanistic basis and identified risk factors. The FDA has mandated strong warnings and a restricted distribution program to mitigate this risk. Patients and healthcare providers must remain vigilant for early signs of PML, as prompt diagnosis and discontinuation of Tysabri are essential to improving outcomes.
This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.
The FDA requires a boxed warning for Tysabri stating that it increases the risk of progressive multifocal leukoencephalopathy (PML), a serious brain infection that usually leads to death or severe disability. The warning identifies three risk factors: presence of anti-JCV antibodies, longer treatment duration (especially beyond 2 years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).
Tysabri is an alpha-4 integrin antagonist that prevents immune cells from crossing the blood-brain barrier, reducing immune surveillance in the central nervous system. This allows the JC virus to reactivate and infect oligodendrocytes, causing demyelination and PML (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).
Symptoms include progressive neurological deficits such as cognitive impairment, motor weakness, and visual disturbances. Diagnosis is confirmed by brain MRI showing white matter lesions and detection of JCV DNA in cerebrospinal fluid. Healthcare professionals should monitor for any new signs suggestive of PML (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).
No. Submission requests an initial records screening only and does not create an attorney-client relationship.
This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.
Request archival records or inquire about member-exclusive transition and benefit programs.